TY  - JOUR
AU  - Liu, Kai-Xiong
AU  - Xu, Bing
AU  - Wang, Jie
AU  - Zhang, Jing
AU  - Ding, Hai-Bo
AU  - Ariani, Felinda
AU  - Qu, Jie-Ming
AU  - Lin, Qi-Chang
PY  - 2014
TI  - Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysis
JF  - Journal of Thoracic Disease; Vol 6, No 3 (March 11, 2014): Journal of Thoracic Disease (Crosstalk between the thoracic physician and the surgeon: perspectives on pulmonary infections, malignancy and chest surgery)
Y2  - 2014
KW  - 
N2  - Purpose: To evaluate the efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis (AECB) and chronic obstructive pulmonary disease (AECOPD).  Methods: We searched PubMed, EMBASE, and the Web of Science for relevant studies. Two reviewers extracted data and reviewed the quality of the studies independently. The primary outcome was clinical success at early follow-up. Study-level data were pooled using a random-effects model when I2 was >50% or a fixed-effects model when I2 was <50%.  Results: Eleven randomized controlled studies were considered. There was no difference between moxifloxacin and comparator agents with regard to treatment success in intention-to-treat (ITT) [odds ratio (OR) =1.18, 95% confidence interval (CI) 0.98-1.42], clinically evaluable (CE) (OR 1.13, 95% CI, 0.93-1.37) patients, or adverse effects in general (OR 1.00, 95% CI, 0.86-1.17). Moxifloxacin was associated with better microbiological success (OR 1.45; 95% CI, 1.14-1.85).  Conclusions: Moxifloxacin was as clinically equivalent and bacteriologically superior to the antibiotic regimens routinely used in patients with AECB and AECOPD. Moxifloxacin therapy may be a promising and safe alternative to empirical treatment for AECB and AECOPD.
UR  - https://jtd.amegroups.org/article/view/2022